Yifeng Pharmary(SH:603939) Zheng Quan Zhi Xing·2025-08-29 16:18Fundraising Overview - The company raised a total of RMB 179,743.20 million through the issuance of 17,974,320 convertible bonds at a face value of RMB 100 each, with net proceeds amounting to RMB 178,026.23 million after deducting underwriting fees [1] - As of June 30, 2025, the company had a remaining balance of RMB 134,543.58 million in raised funds, with an actual surplus of RMB 13,363.58 million, indicating a difference of RMB 121,180.00 million due to temporary use of idle funds for working capital [1] Fund Management - The company has established a dedicated fund management system in compliance with relevant laws and regulations, ensuring the funds are stored in special accounts and managed under strict supervision agreements with banks and sponsors [2][3] Fund Usage - As of June 30, 2025, the total amount invested from the raised funds was RMB 44,306.22 million, with a current period investment of RMB 3,641.62 million [6] - The company reported no abnormal situations regarding the investment projects funded by the raised capital, although some projects do not generate direct measurable economic benefits [6] Project Specifics - The "New Chain Pharmacy Project" is ongoing with an expected internal rate of return of 10.51% and a payback period of 7.14 years, while the "Digital Platform Upgrade Project" has had its completion date extended to December 31, 2025 [7] - The company temporarily used RMB 110,000.00 million of idle funds for working capital and has also allocated up to RMB 30,000.00 million for financial management of idle funds [7]